Utilities for Death and Recover Health States: COPD Cost-Effectiveness Model Data

5.5 KB of model-based cost-utility analysis data evaluating a respiratory panel test for COPD patients. The dataset, authored by Raymond Oppong and last updated in April 2026, contains results from a 40-year healthcare perspective model, indicating the test is cost-saving with a 70% chance of being cost-effective. Potential annual savings from adopting the test are estimated between £118 million and £18.6 billion.

Use Cases

• Modeling cost-effectiveness of diagnostic tests based on the described 40-year healthcare perspective analysis.
• Estimating potential savings from reducing antimicrobial resistance based on the two AMR accounting approaches described.
• Comparing intervention arms in economic evaluations based on the reported £2762.40 cost difference and 0.03 QALY difference.
• Sensitivity analysis for health technology assessment based on the probabilistic results indicating a 70% chance of cost-effectiveness.

Strengths

• Model parameters were informed by a targeted literature review and expert opinions.
• Analysis includes two distinct approaches to account for antimicrobial resistance costs.
• Results are quantified with specific cost and QALY differences (£2762.40 and 0.03).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 5.5 KB file size suggests a very limited scope, likely containing summary model outputs rather than raw patient data.

Provenance

Source

figshare

Collection Method

Model-based cost-utility analysis informed by literature review and expert opinion.

Time Range

Model horizon is 40 years.

Freshness

Last updated 2026-04 27 17:26:47; freshness should be verified.

Geography

null